The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study*

Yan Zhao(Peking University), J Zhang(Ministry of Education of the People's Republic of China), C Zhang(Peking University), Ming-Yun Wang(Sanofi (China)), John T. O’Malley(Brigham and Women's Hospital), Yangfeng Ding(Shanghai Stomatological Hospital), J. Wang(Ningbo No. 2 Hospital), Tomoko Ota, Songmei Geng(Second Affiliated Hospital of Xi'an Jiaotong University), Xiaohong Zhu(First Affiliated Hospital of Wenzhou Medical University), Xueying Liu(University of Hong Kong - Shenzhen Hospital), Zhiqiang Song(Army Medical University), Qianjin Lu(Central South University), Ningning Dang(Shandong Provincial Hospital), Xing‐Hua Gao(First Hospital of China Medical University), Leda Mannent(Sanofi (France)), Q. Liu(Tianjin Medical University General Hospital), Liming Wu(Hangzhou First People's Hospital), Lang Bai(Southern Medical University), Ashish Bansal(Regeneron (United States)), Xu Yao(Chinese Academy of Medical Sciences & Peking Union Medical College), Jianfeng Luo(Sanofi (France)), Wei Li(Xuzhou Medical College), Linfeng Li(Beijing Tongren Hospital), Yong Guo(Zhejiang Chinese Medical University), Luyao Liu(Tongji Hospital), Nikhil Amin(Regeneron (United States)), Jie Gu(Second Military Medical University), Li Dong(Sanofi (China)), Huichun Su(Fujian Medical University), M. Ruddy(Regeneron (United States)), Elizabeth Laws(Sanofi (United States))
British Journal of Dermatology
August 6, 2021
Cited by 73


Related Papers